Ongoing exploration of the immune environments by single cell sequencing, mass cytometry, multiplex immunofluorescence and spatial resolution of communication networks is illuminating the mechanisms driving immunosuppression, differences among metastatic sites and responses to treatments of heterogeneous clinical ER+ breast cancers [7, 8]. The gene discussed is ESR1; the disease is breast cancer.